“Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
Data
2020Autor
Kumar Singh, Awadhesh
Singh, Akriti
Singh, Ritu
Misra, Anoop
Metadata
Mostrar registro completo
Documentos PDF
Imagenes y Videos
Resumo
Backgrounds and aims: The role of hydroxychloroquine (HCQ) in the treatment of COVID-19 is not fully
known. We studied the efficacy of HCQ compared to the control in COVID-19 subjects on - a. viral
clearance measured by reverse transcriptase polymerase chain reaction (RT-PCR) and, b. death due to all
cause.
Methods: PubMed, Scopus, Cochrane and MedRxiv database were searched using the specific keywords
up to April 30, 2020. Studies that met our objectives were assessed for the risk of bias applying various
tools as indicated. Three studies each that reported the outcome of viral clearance by RT-PCR and death
due to all cause, were meta-analyzed by applying inverse variance-weighted averages of logarithmic risk
ratio (RR) using a random effects model. Heterogeneity and publication bias were assessed using the I
2
statistic and funnel plots, respectively.
Results: Meta-analysis of 3 studies (n ¼ 210) on viral clearance assessed by RT-PCR showed no benefit
(RR, 1.05; 95% CI, 0.79 to 1.38; p ¼ 0.74), although with a moderate heterogeneity (I2 ¼ 61.7%, p ¼ 0.07).
While meta-analysis of 3 studies (n ¼ 474) showed a significant increase in death with HCQ, compared to
the control (RR, 2.17; 95% 1.32 to 3.57; p ¼ 0.002), without any heterogeneity (I2 ¼ 0.0%, p ¼ 0.43).
Conclusions: No benefit on viral clearance but a significant increase in mortality was observed with HCQ
compared to control in patients with COVID-19.
Palabras clave
Hydroxychloroquine; COVID-19; Viral clearance; Outcomes; DeathLink para o recurso
https://doi.org/10.1016/j.dsx.2020.05.017Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.